Table 3 Comparisons of changes from baseline to 4 weeks in clinical measures between treatment groups
Bexarotene | Placebo | Difference | ||||
|---|---|---|---|---|---|---|
Factor | Number of subjects | Mean (95 % CI) | Number of subjects | Mean (95 % CI) | Mean (95 % CI) | p Value |
All subjects | ||||||
MMSE | 16 | 0.75 (−0.78, 2.28) | 4 | 1.75 (−1.32, 4.82) | −1.00 (−4.43, 2.43) | 0.57 |
ADAS-Cog | 16 | 0.38 (−2.15, 2.90) | 4 | −0.25 (−5.31, 4.81) | 0.63 (−5.03, 6.28) | 0.83 |
CDR-SOB | 16 | 0.00 (0.00, 0.00) | 4 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | NAa |
NPI | 16 | −2.63 (−6.78, 1.53) | 4 | −2.25 (−10.57, 6.07) | −0.38 (−9.67, 8.92) | 0.94 |
ADCS-ADL | 16 | −1.94 (−4.86, 0.99) | 4 | −6.50 (−12.35, −0.65) | 4.56 (−1.98, 11.10) | 0.18 |
ApoE4 noncarriers | ||||||
MMSE | 4 | −0.25 (−2.12, 1.62) | 3 | 3.67 (1.51, 5.82) | −3.92 (−6.77, −1.06) | 0.026 |
ADAS-Cog | 4 | −3.00 (−7.04, 1.04) | 3 | −0.33 (−4.99, 4.33) | −2.67 (−8.83, 3.50) | 0.41 |
CDR-SOB | 4 | 0.00 (0.00, 0.00) | 3 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | NAa |
NPI | 4 | −1.25 (−12.43, 9.93) | 3 | −3.33 (−16.25, 9.58) | 2.08 (−15.00, 19.16) | 0.81 |
ADCS-ADL | 4 | −4.75 (−10.69, 1.19) | 3 | −7.67 (−14.53, −0.81) | 2.92 (−6.16, 11.99) | 0.53 |